Susan Xu

Susan Xu, PhD

Associate Professor of Biostatistics in Medicine, Academic Institute
Associate Research Member, Research Institute
Houston Methodist
Weill Cornell Medical College


sxu@houstonmethodist.org
Biography

After serving as a Research Assistant in the Department of Statistics and Actuarial Science at the University of Waterloo, Dr. Xu received her academic appointment in 2003 as an Assistant Professor in the Center of American Indian Health Research of the College of Public Health at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma. She joined Houston Methodist Research Institute in 2007. Dr. Xu is an Associate Research Professor of Biostatistics in the Center for Outcomes Research and Houston Methodist DeBakey Heart & Vascular Center at Houston Methodist Research Institute.

Description of Research

Dr. Xu’s biostatistics work has primarily focused on cardiovascular disease (CVD), diabetes, renal disease, and cancer. She was the biostatistician for the NIH-funded Strong Heart Study, the largest and longest longitudinal study of cardiovascular disease and its risk factors in American Indians.

Dr. Xu’s current biostatistics studies include NIH and DoD-funded studies in brain metastatic tumors and breast cancer.

Areas Of Expertise

Diabetes Cardiovascular disease Biostatistics Clinical trial data analysis Survival data analysis Longitudinal data analysis Kidney disease Nutrition
Education & Training

PhD, University of Waterloo, Canada
MS, York University, Toronto, Canada
BSc, Sichuan University
Publications

Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation
Riveros, C, Ranganathan, S, Haque, W, Huang, E, Xu, J, Kulkarni, GS, Geng, M, Anis, M, Muhammad, T, Chan, KS, Farach, A, Teh, BS, Miles, BJ, Klaassen, Z, Sonpavde, GP, Wallis, CJD & Satkunasivam, R 2024, , Journal of the Canadian Urological Association, vol. 18, no. 2, pp. 17-24. https://doi.org/10.5489/cuaj.8386

Prevalence of Delirium After Abdominal Surgery and Association With Ketamine: A Retrospective, Propensity-Matched Cohort Study
Faisal, H, Qamar, F, Hsu, ES, Xu, J, Lai, EC, Wong, ST & Masud, FN 2024, , Critical care explorations, vol. 6, no. 1, pp. E1032. https://doi.org/10.1097/CCE.0000000000001032

Postoperative Discharge Destination Impacts 30-Day Outcomes: A National Surgical Quality Improvement Program Multi-Specialty Surgical Cohort Analysis
Riveros, C, Ranganathan, S, Shah, YB, Huang, E, Xu, J, Geng, M, Melchiode, Z, Hu, S, Miles, BJ, Esnaola, N, Kaushik, D, Jerath, A, Wallis, CJD & Satkunasivam, R 2023, , Journal of Clinical Medicine, vol. 12, no. 21, 6784. https://doi.org/10.3390/jcm12216784

Outflow cannula alignment in continuous flow left ventricular devices is associated with stroke
Kassi, M, Agrawal, T, Xu, J, Marcos-Abdala, HG, Araujo-Gutierrez, R, Macgillivray, T, Suarez, EE, Yousefzai, R, Fida, N, Kim, JH, Hussain, I, Guha, A, Trachtenberg, B, Bhimaraj, A, Chang, SM & Estep, J 2023, , International Journal of Artificial Organs, vol. 46, no. 4, pp. 226-234. https://doi.org/10.1177/03913988231154284

Outflow cannula alignment in continuous flow left ventricular devices is associated with stroke
Kassi, M, Agrawal, T, Xu, J, Marcos-Abdala, HG, Araujo-Gutierrez, R, Macgillivray, T, Suarez, EE, Yousefzai, R, Fida, N, Kim, JH, Hussain, I, Guha, A, Trachtenberg, B, Bhimaraj, A, Chang, SM & Estep, J 2023, , International Journal of Artificial Organs, pp. 3913988231154284. https://doi.org/10.1177/03913988231154284

Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy
Riveros, C, Ranganathan, S, Xu, J, Chang, C, Kaushik, D, Morgan, M, Miles, BJ, Muhammad, T, Anis, M, Aghazadeh, M, Zhang, J, Efstathiou, E, Klaassen, Z, Brooks, MA, Rini, B, Wallis, CJD & Satkunasivam, R 2023, , Urologic Oncology: Seminars and Original Investigations, vol. 41, no. 3, pp. 150.e1-150.e9. https://doi.org/10.1016/j.urolonc.2022.11.022

Helical distraction is superior to linear distraction in maxillary distraction osteogenesis: an in silico study
Gateno, J, Kim, D, Bartlett, S, Gonzalez, C, Xu, J & Xia, JJ 2023, , International Journal of Oral and Maxillofacial Surgery. https://doi.org/10.1016/j.ijom.2023.01.020

Morbidity and mortality of multivisceral resection with radical nephrectomy for locally advanced renal cell carcinoma: An analysis of the National Surgical Quality Improvement Program (NSQIP) database
Lim, K, Riveros, C, Ranganathan, S, Xu, J, Patel, A, Slawin, J, Ordonez, A, Aghazadeh, M, Morgan, M, Miles, BJ, Esnaola, N, Klaassen, Z, Allenson, K, Brooks, M, Wallis, CJD & Satkunasivam, R 2023, , Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2023.01.003

Patient-specific, echocardiography compatible flow loop model of aortic valve regurgitation in the setting of a mechanical assist device
Kassi, M, Filippini, S, Avenatti, E, Xu, S, El-Tallawi, KC, Angulo, CI, Vukicevic, M & Little, SH 2023, , Frontiers in Cardiovascular Medicine, vol. 10, 994431, pp. 994431. https://doi.org/10.3389/fcvm.2023.994431

Persistent or Recurrent Disease in Thyroid Cancer Survivors Who Have Elevated Serum Antithyroglobulin Antibodies
Robbins, RJ, Cubb, TD, Zahid, M & Xu, J 2023, , Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, vol. 29, no. 6, pp. 436-440. https://doi.org/10.1016/j.eprac.2023.02.007

Helical distraction is superior to linear distraction in maxillary distraction osteogenesis: an in silico study
Gateno, J, Kim, D, Bartlett, S, Gonzalez, C, Xu, J & Xia, JJ 2023, , International Journal of Oral and Maxillofacial Surgery, vol. 52, no. 9, pp. 971-980. https://doi.org/10.1016/j.ijom.2023.01.020

Morbidity and mortality of multivisceral resection with radical nephrectomy for locally advanced renal cell carcinoma: An analysis of the National Surgical Quality Improvement Program (NSQIP) database
Lim, K, Riveros, C, Ranganathan, S, Xu, J, Patel, A, Slawin, J, Ordonez, A, Aghazadeh, M, Morgan, M, Miles, BJ, Esnaola, N, Klaassen, Z, Allenson, K, Brooks, M, Wallis, CJD & Satkunasivam, R 2023, , Urologic Oncology: Seminars and Original Investigations, vol. 41, no. 4, pp. 209.e1-209.e9. https://doi.org/10.1016/j.urolonc.2023.01.003

Glomerular hyperfiltration is an independent predictor of postoperative outcomes: A NSQIP multi-specialty surgical cohort analysis
Riveros, C, Ranganathan, S, Huang, E, Ordonez, A, Xu, J, Geng, M, Miles, BJ, Esnaola, N, Klaassen, Z, Jerath, A, Kim, SJ, Wallis, CJD & Satkunasivam, R 2023, , Nephrology, vol. 28, no. 10, pp. 548-556. https://doi.org/10.1111/nep.14221

451 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving Atezolizumab
Xu, J, Burns, EA, Gee, K, Wiechmann, C, Zhang, Y, Kieser, RB, Umoru, G, Shah, S, Sun, K, Abdelrahim, M & Esmail, A 2023, , Journal for immunotherapy of cancer, vol. 11, no. Suppl 1, pp. A502-A502. https://doi.org/10.1136/jitc-2023-SITC2023.0451

1233 Impact of infections occurring in patients receiving immune checkpoint inhibitors for renal cell carcinoma (RCC)
Wiechmann, C, Gee, K, Burns, EA, Xu, J, Zhang, Y, Crenshaw, A, Esmail, A, Kieser, RB, Umoru, G, Muhsen, I, Sun, K, Gong, Z, Shah, S, Singh, M, Zhang, J, Efstathiou, E & Abdelrahim, M 2023, , Journal for immunotherapy of cancer, vol. 11, no. Suppl 1, pp. A1360-A1360. https://doi.org/10.1136/jitc-2023-SITC2023.1233

1234 Impact of infections in patients receiving immune checkpoint inhibitor therapies for non-small cell lung cancer (NSCLC)
Gee, K, Wiechmann, C, Burns, EA, Xu, J, Zhang, Y, Esmail, A, Crenshaw, A, Kieser, RB, Umoru, G, Muhsen, I, Sun, K, Gong, Z, Shah, S, Singh, M, Zhang, J, Bernicker, E & Abdelrahim, M 2023, , Journal for immunotherapy of cancer, vol. 11, no. Suppl 1, pp. A1361-A1361. https://doi.org/10.1136/jitc-2023-SITC2023.1234

P-409 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving atezolizumab: Abstract Book of the ESMO 25th World Congress on Gastrointestinal Cancer 2023, Barcelona, Spain, 28 June - 1 July 2023
Esmail, A, Xu, J, Burns, E, Gee, K, Wiechmann, C, Zhang, Y, Kieser, R, Gong, Z, Umoru, G, Shah, S, Sun, K, Heyne, K & Abdelrahim, M 2023, , Annals of Oncology, vol. 34, pp. S156. https://doi.org/10.1016/j.annonc.2023.04.465, https://doi.org/10.1016/j.annonc.2023.04.465

Outcomes with Second-line Treatment Following First Line Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France.
Abudayyeh, A, Esmail, A, Kaseb, A, Xu, J, Abboud, K, Umoru, G & Abdelrahim, M 2023, , HPB, vol. 25, pp. S321. https://doi.org/10.1016/j.hpb.2023.07.252

Gemcitabine Plus Cisplatin versus Non-gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France.
Abdelrahim, M, Esmail, A, Xu, J, Umoru, G, Saharia, A & Ghobrial, RM 2023, , HPB, vol. 25, pp. S223. https://doi.org/10.1016/j.hpb.2023.07.064

Utilization of Atezolizumab Plus Bevacizumab as Subsequent-line Therapy in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France.
Abudayyeh, A, Esmail, A, Kaseb, A, Xu, J, Umoru, G, Abboud, K & Abdelrahim, M 2023, , HPB, vol. 25, pp. S321-S322. https://doi.org/10.1016/j.hpb.2023.07.253